J. Haurum

发表

Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing.

P. S. Andersen, Allan Jensen, Per-Johan Meijer, 2006, Journal of molecular biology.

Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.

S. Bregenholt, J. Lantto, A. Jensen, 2006, Current pharmaceutical design.

Capturing the Natural Diversity of the Human Antibody Response against Vaccinia Virus

S. K. Rasmussen, S. Bregenholt, J. Lantto, 2010, Journal of Virology.

Allergen-Specific Polyclonal Antibodies Reduce Allergic Disease in a Mouse Model of Allergic Asthma

T. P. Frandsen, M. Oleksiewicz, S. Bregenholt, 2006, International Archives of Allergy and Immunology.

Use of factorial experimental design to delineate the strong calcium- and pH-dependent changes in binding of human surfactant protein-A to neutral glycosphingolipids--a model for studies of protein-carbohydrate interactions.

G. Larson, J. Haurum, L. Hynsjö, 1995, Analytical biochemistry.

Recognition of carbohydrate by major histocompatibility complex class I- restricted, glycopeptide-specific cytotoxic T lymphocytes

R. Dwek, T. Elliott, A. McMichael, 1994, The Journal of experimental medicine.

An improved assembly assay for peptide binding to HLA-B*2705 and H-2K(k) class I MHC molecules.

T. Elliott, J. Haurum, M. Andersen, 1997, Journal of immunological methods.

Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.

T. Elliott, J. Neefjes, J. Zeuthen, 1999, Journal of immunology.

Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.

V. Apostolopoulos, V. Karanikas, J. Haurum, 1997, Journal of immunology.

Polyclonals : A Third Generation of Antibody Therapeutics Recombinant polyclonal antibodies overcome many of the challenges faced by , first , immunoglobulin therapy , and second , monoclonal antibodies to offer a third generation of antibody therapeutics

Kaja Tengbjerg, J. Haurum, 2007 .

Interaction of C1q receptor with lung surfactant protein A

S. Thiel, Robert B Sim, R. Malhotra, 1992, European journal of immunology.

MUC1 peptide epitopes associated with five different H‐2 class I molecules

V. Apostolopoulos, I. Mckenzie, J. Haurum, 1997, European journal of immunology.

An assay for peptide binding to HLA-Cw*0102.

T. Elliott, J. Zeuthen, J. Haurum, 1999, Tissue antigens.

Pathogen-specific recombinant human polyclonal antibodies: biodefence applications

S. Bregenholt, J. Haurum, 2004, Expert opinion on biological therapy.

Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen.

P. S. Andersen, V. Coljee, S. Bregenholt, 2007, Molecular immunology.

Class I Major Histocompatibility Complex-restricted Cytotoxic T Lymphocytes Specific for Epstein-Barr Virus (EBV) Nuclear Antigens Fail to Lyse the EBV-transformed B Lymphoblastoid Cell Lines

A. McMichael, M. Rowe, A. Rickinson, 2003 .

Anti-Variable Domain Antibody Responses Polyclonal Antibodies to Inhibitory Reduced Susceptibility of Recombinant Haurum and Søren

P. S. Andersen, V. Coljee, S. Bregenholt, 2006 .

Synthesis of major histocompatibility complex class I binding glycopeptides

R. Dwek, T. Elliott, A. Lellouch, 1995 .

Recognition of Carbohydrate by Major Histocompatibility Complex Class 1-restricted, Glyeopeptide-specific

R. Dwek, T. Elliott, A. McMichael, 2003 .

Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised

A. McMichael, M. Rowe, A. Rickinson, 1995, The Journal of experimental medicine.

Studies on the carbohydrate-binding characteristics of human pulmonary surfactant-associated protein A and comparison with two other collectins: mannan-binding protein and conglutinin.

S. Thiel, J. Jensenius, J. Jensenius, 1993, The Biochemical journal.

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

C. Pyke, M. Kragh, J. Haurum, 2010, Cancer research.

Presentation of Cytosolic Glycosylated Peptides by Human Class I Major Histocompatibility Complex Molecules in Vivo

T. Elliott, J. Neefjes, J. Zeuthen, 1999, The Journal of experimental medicine.

Complement activation upon binding of mannan‐binding protein to HIV envelope glycoproteins

S. Thiel, J. Jensenius, I. Jones, 1993, AIDS.

MHC-restricted T cell responses against posttranslationally modified peptide antigens.

T. Elliott, J. Haurum, M. Andersen, 2001, Advances in immunology.

Binding of human collectins (SP-A and MBP) to influenza virus.

S. Thiel, Robert B Sim, R. Malhotra, 1994, The Biochemical journal.

The INNs and outs of antibody nonproprietary names

Andreas Plückthun, James S. Huston, John M. Lambert, 2015, mAbs.

Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity.

R. Dwek, T. Elliott, M. Wormald, 1999, Immunity.

Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition

R. Dwek, T. Elliott, A. McMichael, 1995, European journal of immunology.

Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised

A. McMichael, M. Rowe, A. Rickinson, 1995, The Journal of experimental medicine.

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis

Sarah Batey, K. Leung, V. Drewett, 2015, Molecular Therapy.

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis

Sarah Batey, K. Leung, V. Drewett, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo.

H. Rammensee, S. Stevanović, T. Elliott, 2000, Tissue antigens.

Limits for Antibody Affinity Maturation and Repertoire Diversification in Hypervaccinated Humans

P. S. Andersen, A. Jensen, T. R. Poulsen, 2011, The Journal of Immunology.

Reduced Susceptibility of Recombinant Polyclonal Antibodies to Inhibitory Anti-Variable Domain Antibody Responses

P. S. Andersen, V. Coljee, S. Bregenholt, 2006, The Journal of Immunology.

Recombinant polyclonal antibodies: the next generation of antibody therapeutics?

John S Haurum, J. Haurum, 2006, Drug discovery today.

Production of target‐specific recombinant human polyclonal antibodies in mammalian cells

A. Tolstrup, J. Sharon, T. P. Frandsen, 2006, Biotechnology and bioengineering.

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

P. S. Andersen, M. Kragh, P. Meijer, 2011, mAbs.

Pollen grains bind to lung alveolar type II cells (A549) via lung surfactant protein A (SP-A)

S. Thiel, J. Jensenius, Robert B Sim, 1993, Bioscience reports.

Technologies for the Generation of Human Antibodies

R. R. Bhatt, C. Davis, J. Haurum, 2012 .

Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle.

S. Bregenholt, J. Haurum, 2005, IDrugs : the investigational drugs journal.

Anticorps polyclonal recombine anti-rhesus d et procedes de production

A. Tolstrup, J. Haurum, S. Rasmussen, 2005 .

[The cell mediated immune response].

J. Haurum, 1995, Ugeskrift for læger.